HomeAI · summaries
Storia in 5 fonti
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- ·
biopharmadive.com
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
